摘要
识别和分析药物不良反应是临床药师工作的切入点之一。鉴于目前未见肺癌合并3级贫血患者使用贝伐珠单抗的安全性报道,本文报道1例临床药师对肺癌合并3级贫血患者使用贝伐珠单抗维持治疗的药学监护,为临床医师提供治疗参考。临床药师从药学的角度分析贝伐珠单抗的血液学毒性,并为患者提供全面的药学监护,促进合理用药。
Adverse drug reaction identification and analysis is one of the entry points for clinical pharmacists.Since there is no report on the safety of bevacizumab used in patients with lung cancer and grade 3 anemia,here we reported a case of successful pharmaceutical care for a patient with lung cancer and grade 3 anemia during the maintenance treatment of bevacizumab,so as to provide a therapeutic reference for clinicians.The clinical pharmacist analyzed the hematotoxicity of bevacizumab from the perspective of pharmacy,gave patients comprehensive pharmaceutical care,and promoted rational drug using.
作者
吴端仪
曾卫强
劳海燕
何杏仪
WU Duanyi;ZENG Weiqiang;LAO Haiyan;HE Xingyi(Department of Clinical Pharmacy,Shunde Hospital Guangzhou University of Chinese Medicine,Foshan,Guangdong,528300,China;Department of Pharmacy,Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences,Guangzhou,Guangdong,510080,China)
出处
《肿瘤药学》
CAS
2021年第6期758-762,共5页
Anti-Tumor Pharmacy
关键词
临床药师
药学监护
贝伐珠单抗
贫血
Clinical pharmacist
Pharmaceutical care
Bevacizumab
Anemia
